With a potential $5+ billion drug that could ultimately be used against dozens of diseases, the clinical-stage biotech company discussed in today’s article “is a ripe acquisition target, and when that acquisition comes, it will go for a steep price.”
Shares of the relatively unknown biopharmaceutical company discussed in today’s article have experienced extreme volatility this month, hitting their all-time low on June 2nd before proceeding to soar to their all-time high on June 10th.
Perceptive Life Sciences, a fund that has outperformed the market, sold all of its 1 million shares of Novavax in the first few months of 2021 and bought millions more shares of three biopharma/biotech stocks in the same period.
Examining four oncology stocks that could be smart picks right now.
After trailing the broader market for the past few months, biotech has gotten some love in recent days – from the FDA in the form of its approval of Biogen’s controversial Alzheimer’s drug, and also from the Reddit crowd.
Mental health issues are on the rise – and so is demand for treatments for mental health disorders based on psychedelic substances.
As PDUFA dates can serve as catalysts for stocks, biotech investors can be well served by paying attention to them.
What do these impending decisions mean for healthcare and biotech stocks?
A year or so ago, the gene therapy trend was hot – until it quickly cooled down. But now may be the time to get back in on this trend, especially with one particular biotech stock.
The biotech featured in today’s article “selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a significant benefit over existing products.”